Yankees Score with ...
Health Care: Drugs
Merrimack Pharmaceuticals Inc (MACK: NASDAQ)
$5.20 -0.06 | -1.14%
05/24/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | ||
| Sales | 48.92M | 34.22M | 20.30M | |
| Cost of Sales | 122.19M | 96.03M | 54.65M | |
| Gross Operating Profit | -73.27M | -61.82M | -34.34M | |
| Selling, General, and Administrative Expenses | 15.80M | 14.45M | 11.38M | |
| Research & Development | 0.00 | 0.00 | 0.00 | |
| Operating Income before D & A (EBITDA) | -89.08M | -76.27M | -45.73M | |
| Depreciation & Amortization | 3.66M | 4.60M | 3.63M | |
| Interest Income | 184.00K | 56.00K | 74.00K | |
| Other Income - Net | 1.36M | 1.15M | 2.67M | |
| Special Income / Charges | 0.00 | 0.00 | 178.00K | |
| Total Income Before Interest Expenses (EBIT) | -91.20M | -79.66M | -46.43M | |
| Interest Expense | 553.00K | 13.00K | 3.73M | |
| Pre-Tax Income | -91.75M | -79.68M | -50.16M | |
| Income Taxes | 0.00 | 0.00 | 0.00 | |
| Minority Interest | -477.00K | -453.00K | -55.00K | |
| Net Income From Continuing Operations | -91.75M | -79.22M | -50.10M | |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | |
| Net Income From Total Operations | -91.75M | -79.22M | -50.10M | |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | |
| Total Net Income | -91.28M | -79.22M | -50.10M | |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-91.75M | -79.22M | -50.28M | |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -91.75M | -79.22M | -50.10M | |
| Basic EPS from Continuing Ops. | -1.28 | -7.67 | 0.00 | |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | |
| Basic EPS from Total Operations | -1.28 | -7.67 | 0.00 | |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | |
| Basic EPS, Total | -1.28 | -7.67 | 0.00 | |
| Basic Normalized Net Income/Share | -1.28 | -7.67 | n.a. | |
| EPS fr Continuing Ops. | -1.28 | -7.67 | 0.00 | |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | |
| EPS fr Total Ops. | -1.28 | -7.67 | 0.00 | |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | |
| EPS, Total | -1.28 | -7.67 | 0.00 | |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.28 | -7.67 | n.a. | |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | |
Portfolios with MACK
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks With Big Insider Buy...
- ProTPG-Axon Capital
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
Latest MACK Headlines from TheStreet
- Merrimack Pharmaceuticals Completes Enrollment Of One Cohort In Neoadjuvant Phase 2 Study Of MM-121 In HER2-Negative Breast Cancer 04.15.13 | 08:04 am
- Merrimack Pharmaceuticals Announces Webcast Of Inaugural Research & Development Day 04.05.13 | 12:04 pm
- Merrimack Pharmaceuticals Completes Enrollment In A Phase 2 Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers 03.18.13 | 08:03 am
- Merrimack Reports Fourth Quarter And Full Year 2012 Financial Results 03.14.13 | 08:03 am
- 5 Stocks Poised for Breakouts 03.01.13 | 02:03 pm
- Merrimack Pharmaceuticals Announces Timing Of Fourth Quarter 2012 Investor Conference Call 02.27.13 | 09:02 am
- Merrimack To Present At The Cowen And Company 33rd Annual Health Care Conference 02.25.13 | 12:02 pm
- Merrimack To Participate In Pancreatic Cancer Panel At The 2013 BIO CEO & Investor Conference 02.07.13 | 12:02 pm
- Merrimack Pharmaceuticals To Present Preclinical Data On Bispecific Antibody MM-111 In ErbB2-Positive Gastric Cancers 01.23.13 | 08:01 am
- Merrimack Pharmaceuticals Initiates Cross-Tumor Study To Investigate Potential Predictive Response Markers For A Developmental Nanotherapeutic Chemotherapy 12.19.12 | 02:12 pm
Press Releases for MACK
- Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model - PR Newswire 04.10.13 | 09:04 am
- Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor - PR Newswire 04.04.13 | 08:04 am
- Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies - PR Newswire 04.02.13 | 09:04 am
- Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data For Novel Agent To Treat HER2-positive Breast Cancer And Preclinical Data On Companion Diagnostic - PR Newswire 12.10.12 | 09:12 am
- Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer - PR Newswire 11.27.12 | 09:11 am
- Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers - PR Newswire 10.02.12 | 08:10 am
- Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers - PR Newswire 09.18.12 | 11:09 am
- Merrimack Pharmaceuticals, Inc. Announces Pricing Of Initial Public Offering - PR Newswire 03.28.12 | 11:03 pm
Partner Headlines for MACK
- After Hours Most Active for Nov 16, 2012 : SFD, QQQ, WIN, TSN, MSFT, TSS, BAC, MYL, ZGNX, WM, MACK, MMC - NASDAQ 11.16.12 | 09:11 pm
- Morning Market Losers - Benzinga 09.25.12 | 09:09 am
- 5 Low-Debt Biotech Stocks Forecasted For Growth - Seeking Alpha 09.22.12 | 09:09 am
- Jim Cramer Watchdog: SELL Morgan Stanley and 'BUY, BUY, BUY' These 3 HOT Stocks - Wall St. Cheat Sheet 07.20.12 | 11:07 am
